Streetbeat News

Stock Prices

CAL

Caleres reported Q2 2024 earnings of $0.85 per share, missing the $1.22 estimate, and sales of $683.32M, below the $723.80M estimate. Both earnings and sales decreased compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 10:46 am

EGAN

FIVN

RNG

The article highlights three oversold tech stocks with RSI values near or below 30, indicating potential buying opportunities. eGain Corp, Five9 Inc, and RingCentral Inc are mentioned, with recent financial updates and stock price movements.

Portfolio Pulse from Avi Kapoor

September 12, 2024 | 10:40 am

GSK

GSK announced positive results from a Phase 2 trial of its mRNA seasonal influenza vaccine, showing effective immune responses against A and B strains in both younger and older adults.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 10:38 am

SMMT

Summit Therapeutics has successfully raised $235 million by selling 10.35 million shares at $22.70 each. The capital raise included $79 million from insiders and $156 million from institutional investors.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 10:36 am

AURA

Aura Biosciences reported positive Phase 2 results for Bel-sar as a first-line treatment for early-stage choroidal melanoma, showing an 80% tumor control rate, 90% visual acuity preservation, and a highly favorable safety profile.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 10:33 am

CURV

Torrid Holdings announced the pricing of a public offering of 8 million shares at $4.00 per share, to be sold by certain stockholders. The offering is expected to close on September 13, 2024. Torrid will not receive any proceeds from this sale.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 10:31 am

MRNA

Moderna's stock is experiencing a decline following the company's announcement to reduce its R&D expenses by $1.1 billion by 2027.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 10:22 am

ALK

Alaska Air's shares are rising as the company has increased its Q3 adjusted EPS guidance due to better revenue and fuel cost projections.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 10:18 am

GBTC

IBIT

JPM

JPMorgan CEO Jamie Dimon, known for his past criticism of Bitcoin, has seen his stance soften as the bank now holds positions in Bitcoin-related ETFs. Despite previously calling Bitcoin a 'fraud,' JPMorgan has invested in Grayscale Bitcoin Trust and liquidated its iShares Bitcoin Trust ETF holdings.

Portfolio Pulse from Aniket Verma

September 12, 2024 | 10:11 am

MRNA

Moderna is implementing portfolio prioritization and cost efficiencies to reduce its R&D expenses by $1.1 billion, from an estimated $4.8 billion in 2024 to $3.6-$3.8 billion by 2027.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 10:06 am